Literature DB >> 658114

Pharmacokinetics and side-effects of clonidine.

A Keränen, S Nykänen, J Taskinen.   

Abstract

A single oral dose of clonidine 300 microgram was administered to 8 healthy, normotensive subjects and the time course of its plasma concentrations was followed for 24 h. The plasma concentration of clonidine rose to a peak of 1.17 +/- 0.12 ng/ml at about 2 h: the absorption half-life was 0.6 +/- 0.2 h. Elimination followed first order kinetics with a half-life of 7.7 +/- 2.0 h. The correlation between the two most common side-effects of clonidine, sedation and dryness of the mouth, with the time course of its plasma concentrations was highly significant, p less than 0.01. All the subjects complained of severe sedation. During continuous administration of clonidine (75 microgram t.i.d.) for one week a steady state serum level of 0.30-0.35 ng/ml was achieved. One 75 microgram tablet of clonidine raised the serum level to about 0.69 +/- 0.13 ng/ml in two hours. After cessation of dosing, the serum level declined with a half-life of 7.5 +/- 1.5 h. The urinary excretion of unchanged clonidine was found to be about one third of the administered dose in 24 h during continuous administration and in the first 24 h after the single oral dose.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 658114     DOI: 10.1007/BF00609752

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  [Catapressan metabolism. Hypotensive effect of 4-hydroxycatapressan].

Authors:  J D Ehrhardt
Journal:  Therapie       Date:  1972 Sep-Oct       Impact factor: 2.070

3.  Localization of the central cardiovascular action of clonidine.

Authors:  P Bousquet; P G Guertzenstein
Journal:  Br J Pharmacol       Date:  1973-12       Impact factor: 8.739

4.  Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients.

Authors:  M R Putzeys; S W Hoobler
Journal:  Am Heart J       Date:  1972-04       Impact factor: 4.749

5.  Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl.

Authors:  W Kobinger; A Walland
Journal:  Eur J Pharmacol       Date:  1967-12       Impact factor: 4.432

6.  Some observations on the inhibition of salivation by St 155 [2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride, Catapres, Catapresan].

Authors:  M J Rand; M Rush; J Wilson
Journal:  Eur J Pharmacol       Date:  1969-01       Impact factor: 4.432

7.  Properties of catapres, a new hypotensive drug: a preliminary report.

Authors:  J Ng; D D McGrgor; K M Taylor; H Smirk
Journal:  N Z Med J       Date:  1967-12

8.  [First observations on an antihypertensive effect of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride in man].

Authors:  D Michel; W Zimmermann; A Nassehi; P Seraphim
Journal:  Dtsch Med Wochenschr       Date:  1966-09-02       Impact factor: 0.628

9.  [Clinical and clinical-experimental studies with a new blood pressure lowering substance: dichlorophenylaminoimidazoline].

Authors:  K D Bock; V Heimsoth; P Merguet; J Schönermark
Journal:  Dtsch Med Wochenschr       Date:  1966-10-07       Impact factor: 0.628

10.  The physiological disposition of 2(2,6-dichloroanilino)-2-imidazoline (St-155).

Authors:  A K Cho; S H Curry
Journal:  Biochem Pharmacol       Date:  1969-02       Impact factor: 5.858

View more
  16 in total

1.  Clonidine extended-release in attention-deficit hyperactivity disorder: profile report.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 2.  Clonidine extended-release: in attention-deficit hyperactivity disorder.

Authors:  Jamie D Croxtall
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

3.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

4.  Clonidine has a paradoxical effect on cyclic arousal and sleep bruxism during NREM sleep.

Authors:  Maria Clotilde Carra; Guido M Macaluso; Pierre H Rompré; Nelly Huynh; Liborio Parrino; Mario Giovanni Terzano; Gilles J Lavigne
Journal:  Sleep       Date:  2010-12       Impact factor: 5.849

5.  Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex.

Authors:  Cédric M Hysek; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 6.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

7.  Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus.

Authors:  M I Read; J C Harrison; D S Kerr; I A Sammut
Journal:  Br J Pharmacol       Date:  2015-08-24       Impact factor: 8.739

Review 8.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

9.  Hypotensive action and side-effects of flutonidin in normal subjects. A double-blind controlled trial.

Authors:  P Sala; S M Chierichetti; P Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

Review 10.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.